Figure 8.

The m⁶A score model predicts the benefits of radiotherapy and immunotherapy. (A–C) Kaplan-Meier curves of overall survival for patients in m⁶A cluster A (A), m⁶A cluster B (B), and m⁶A cluster C (C) based on acceptance/rejection of radiotherapy. Log-rank test. (D, E) Kaplan-Meier curves of overall survival for patients with a high (D)/low (E) m⁶A score based on acceptance/rejection of radiotherapy. Log-rank test. (F, G) Comparison of the PD-1 (F)/CTLA4 (G) expression levels between the high and low m⁶A score groups. Log-rank test. (ns p > 0.05;^* p < 0.05; ^** p < 0.01; ^*** p < 0.001). (H) Differences in the expression of other immune checkpoints between the high and low m⁶A score groups. Log-rank test. (^* p < 0.05; ^** p < 0.01; ^*** p < 0.001). (I–L) Box plot representing the relative distribution of the immunophenoscore between the low and high m⁶A score groups in LUAD patients based on TCIA database, (I) CTLA4⁻ PD1⁻; (J) CTLA4⁻ PD1⁺; (K) CTLA4⁺ PD1⁻; and (L) CTLA4⁺ PD1⁺. The asterisks represented the statistical p-value (*p < 0.05; ***p < 0.001).